Won Gu Kim1, Sheue-yann Cheng. 1. Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Abstract
BACKGROUND: Thyroid hormone receptors (TRs) are ligand-dependent transcription factors that mediate the actions of the thyroid hormone (T3) in development, growth, and differentiation. The THRA and THRB genes encode several TR isoforms that express in a tissue- and development-dependent manner. In the past decades, a significant advance has been made in the understanding of TR actions in maintaining normal cellular functions. However, the roles of TRs in human cancer are less well understood. The reduced expression of TRs because of hypermethylation, or deletion of TR genes found in human cancers suggests that TRs could function as tumor suppressors. A close association of somatic mutations of TRs with human cancers further supports the notion that the loss of normal functions of TR could lead to uncontrolled growth and loss of cell differentiation. SCOPE OF REVIEW: In line with the findings from association studies in human cancers, mice deficient in total functional TRs (Thra1(-/-)Thrb(-/-) mice) or with a targeted homozygous mutation of the Thrb gene (denoted PV; Thrb(PV/PV) mice) spontaneously develop metastatic thyroid carcinoma. This review will examine the evidence learned from these genetically engineered mice that provided strong evidence to support the critical role of TRs in human cancer. MAJOR CONCLUSIONS: Loss of normal functions of TR by deletion or by mutations could contribute to cancer development, progression and metastasis. GENERAL SIGNIFICANCE: Novel mechanistic insights are revealed in how aberrant TR activities lead to carcinogenesis. Mouse models of thyroid cancer provide opportunities to identify molecular targets as potential treatment modalities. This article is part of a Special Issue entitled Thyroid hormone signalling. Published by Elsevier B.V.
BACKGROUND: Thyroid hormone receptors (TRs) are ligand-dependent transcription factors that mediate the actions of the thyroid hormone (T3) in development, growth, and differentiation. The THRA and THRB genes encode several TR isoforms that express in a tissue- and development-dependent manner. In the past decades, a significant advance has been made in the understanding of TR actions in maintaining normal cellular functions. However, the roles of TRs in humancancer are less well understood. The reduced expression of TRs because of hypermethylation, or deletion of TR genes found in humancancers suggests that TRs could function as tumor suppressors. A close association of somatic mutations of TRs with humancancers further supports the notion that the loss of normal functions of TR could lead to uncontrolled growth and loss of cell differentiation. SCOPE OF REVIEW: In line with the findings from association studies in humancancers, mice deficient in total functional TRs (Thra1(-/-)Thrb(-/-) mice) or with a targeted homozygous mutation of the Thrb gene (denoted PV; Thrb(PV/PV) mice) spontaneously develop metastatic thyroid carcinoma. This review will examine the evidence learned from these genetically engineered mice that provided strong evidence to support the critical role of TRs in humancancer. MAJOR CONCLUSIONS: Loss of normal functions of TR by deletion or by mutations could contribute to cancer development, progression and metastasis. GENERAL SIGNIFICANCE: Novel mechanistic insights are revealed in how aberrant TR activities lead to carcinogenesis. Mouse models of thyroid cancer provide opportunities to identify molecular targets as potential treatment modalities. This article is part of a Special Issue entitled Thyroid hormone signalling. Published by Elsevier B.V.
Authors: P A Futreal; P Söderkvist; J R Marks; J D Iglehart; C Cochran; J C Barrett; R W Wiseman Journal: Cancer Res Date: 1992-05-01 Impact factor: 12.701
Authors: Eric L Bolf; Noelle E Gillis; Cole D Davidson; Princess D Rodriguez; Lauren Cozzens; Jennifer A Tomczak; Seth Frietze; Frances E Carr Journal: Mol Cancer Res Date: 2020-06-17 Impact factor: 5.852
Authors: F Rosignolo; V Maggisano; M Sponziello; M Celano; C R T Di Gioia; M D'Agostino; L Giacomelli; A Verrienti; M Dima; V Pecce; C Durante Journal: J Endocrinol Invest Date: 2015-05-24 Impact factor: 4.256
Authors: Antonio C Bianco; Alexandra Dumitrescu; Balázs Gereben; Miriam O Ribeiro; Tatiana L Fonseca; Gustavo W Fernandes; Barbara M L C Bocco Journal: Endocr Rev Date: 2019-08-01 Impact factor: 19.871
Authors: Dana Macejova; Jan Podoba; Lucia Toporova; Marianna Grigerova; Karol Kajo; Katarina Machalekova; Julius Brtko Journal: Oncol Lett Date: 2019-08-22 Impact factor: 2.967
Authors: A J Fritz; N E Gillis; D L Gerrard; P D Rodriguez; D Hong; J T Rose; P N Ghule; E L Bolf; J A Gordon; C E Tye; J R Boyd; K M Tracy; J A Nickerson; A J van Wijnen; A N Imbalzano; J L Heath; S E Frietze; S K Zaidi; F E Carr; J B Lian; J L Stein; G S Stein Journal: Genes Chromosomes Cancer Date: 2019-03-15 Impact factor: 5.006
Authors: Frances E Carr; Phillip W L Tai; Michael S Barnum; Noelle E Gillis; Katherine G Evans; Thomas H Taber; Jeffrey H White; Jennifer A Tomczak; Diane M Jaworski; Sayyed K Zaidi; Jane B Lian; Janet L Stein; Gary S Stein Journal: Endocrinology Date: 2016-06-02 Impact factor: 4.736